Pentasa en es it fr

Pentasa Brand names, Pentasa Analogs

Pentasa Brand Names Mixture

  • No information avaliable

Pentasa Chemical_Formula

C6H11NO3

Pentasa RX_link

No information avaliable

Pentasa fda sheet

Pentasa FDA

Pentasa msds (material safety sheet)

Pentasa Synthesis Reference

No information avaliable

Pentasa Molecular Weight

145.156 g/mol

Pentasa Melting Point

No information avaliable

Pentasa H2O Solubility

Freely soluble

Pentasa State

Solid

Pentasa LogP

-1.026

Pentasa Dosage Forms

Cream for topical administration (160 mg/g of methyl aminolevulinate equivalent to 16.0% of methyl aminolevulinate)

Pentasa Indication

For topical use, in combination with 570 to 670 nm wavelength red light illumination, in the treatment of non-hyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used in conjunction with lesion preparation (debridement using a sharp dermal curette).

Pentasa Pharmacology

After topical application of methyl aminolevulinate, porphyrins will accumulate intracellularly in the treated skin lesions. The intracellular porphyrins (including PpIX) are photoactive, fluorescing compounds and, upon light activation in the presence of oxygen, singlet oxygen is formed which causes damage to cellular compartments, in particular the mitochondria. Light activation of accumulated porphyrins leads to a photochemical reaction and thereby phototoxicity to the light-exposed target cells.

Pentasa Absorption

In vitro, after 24 hours the mean cumulative absorption through human skin was 0.26% of the administered dose.

Pentasa side effects and Toxicity

The severity of local phototoxic reactions such as erythema, pain and burning sensation may increase in case of prolonged application time or very high light intensity.

Pentasa Patient Information

Pentasa Organisms Affected

Humans and other mammals